BR112013002945A2 - composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito - Google Patents

composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito

Info

Publication number
BR112013002945A2
BR112013002945A2 BR112013002945A BR112013002945A BR112013002945A2 BR 112013002945 A2 BR112013002945 A2 BR 112013002945A2 BR 112013002945 A BR112013002945 A BR 112013002945A BR 112013002945 A BR112013002945 A BR 112013002945A BR 112013002945 A2 BR112013002945 A2 BR 112013002945A2
Authority
BR
Brazil
Prior art keywords
interest
treating
subject
nucleic acid
pharmaceutical composition
Prior art date
Application number
BR112013002945A
Other languages
English (en)
Inventor
Francine Behar-Cohen
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of BR112013002945A2 publication Critical patent/BR112013002945A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito. a presente invenção refere-se a métodos e composições farmacêuticas para o tratamento de uma doença ocular em um sujeito. mais particularmente, a presente invenção refere-se a um método para tratar uma doença ocular em um sujeito compreendendo as etapas que consistem em i) entregar uma composição farmacêutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse no músculo ciliar do sujeito e ii) expor a região onde a composição farmacêutica foi entregue à ultrassom para induzir a transfecção do referido ácido nucleico terapêutico de interesse no referido músculo ciliar.
BR112013002945A 2010-08-09 2011-08-08 composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito BR112013002945A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305873 2010-08-09
PCT/EP2011/063631 WO2012020001A1 (en) 2010-08-09 2011-08-08 Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject

Publications (1)

Publication Number Publication Date
BR112013002945A2 true BR112013002945A2 (pt) 2016-06-07

Family

ID=42830086

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002945A BR112013002945A2 (pt) 2010-08-09 2011-08-08 composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito

Country Status (10)

Country Link
US (1) US20130261535A1 (pt)
EP (1) EP2603238B1 (pt)
JP (1) JP2013536187A (pt)
BR (1) BR112013002945A2 (pt)
CA (1) CA2807628A1 (pt)
DK (1) DK2603238T3 (pt)
ES (1) ES2515467T3 (pt)
PT (1) PT2603238E (pt)
RU (1) RU2013105016A (pt)
WO (1) WO2012020001A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931203B2 (en) * 2011-08-02 2018-04-03 Valdemar Portney Presbyopia correcting wireless optical system
WO2013149260A1 (en) * 2012-03-30 2013-10-03 Humayun Mark S Method for treatment of ocular disorders
EP3453366A4 (en) * 2016-05-06 2020-01-08 Public University Corporation Nagoya City University OPHTHALMIC DEVICE FOR EXTENDED RELEASE OF MEDICATION
JP7199379B2 (ja) * 2017-05-04 2023-01-05 ソルボンヌ・ユニヴェルシテ ヒトの血液網膜関門の一時的な破綻、および網膜障害の治療のためのそれらの使用
EP3905995A4 (en) 2019-01-04 2022-08-31 California Institute of Technology PROCEDURE FOR EYE LENS REMOVAL USING CAVITATION MICROBUBBLE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5787216A (en) 1980-11-19 1982-05-31 Nippon Gakki Seizo Kk Amplifying circuit
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (pt) 1990-04-02 1993-05-01 Sint Sa
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5773527A (en) 1990-08-27 1998-06-30 Dendritech, Inc. Non-crosslinked, polybranched polymers
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
WO2004073750A1 (en) 1995-06-07 2004-09-02 Harald Dugstad Improvements in or relating to contrast agents
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
EP1551459A4 (en) 2002-07-11 2007-02-07 Targeson Llc MICROBULLE-BASED COMPOSITIONS, AND METHODS FOR THEIR PREPARATION AND USE
US7083783B2 (en) * 2004-02-18 2006-08-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
EP1714642A1 (en) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
JP5000638B2 (ja) * 2005-04-18 2012-08-15 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） 対象の眼球に対して治療用生成物を送達するための改良型方法及び装置
US8454937B2 (en) * 2006-09-12 2013-06-04 Temple University—Of The Commonwealth System of High Education Method and composition for the site-selective delivery using viruses encapsulated in microbubbles

Also Published As

Publication number Publication date
RU2013105016A (ru) 2014-09-20
DK2603238T3 (da) 2014-10-20
US20130261535A1 (en) 2013-10-03
PT2603238E (pt) 2014-10-22
JP2013536187A (ja) 2013-09-19
EP2603238A1 (en) 2013-06-19
ES2515467T3 (es) 2014-10-29
WO2012020001A1 (en) 2012-02-16
EP2603238B1 (en) 2014-07-30
CA2807628A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
CO7151524A2 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciación y usos de los mismos
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
WO2014022739A3 (en) Modified rnai agents
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112013002945A2 (pt) composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112013006355A2 (pt) profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]